Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter Narcan (naloxone HCl) Nasal Spray

Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA. NARCAN® (naloxone HCI) Nasal Spray 4 mg, the first intranasal form of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials